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Introduction
Glycosylation is one of the most important modiﬁ  cations 
of proteins and lipids. Th   e structure of glycans is highly 
diversiﬁ   ed and their biosynthesis requires speciﬁ  c 
enzymatic machinery involving a high number of glyco-
syl  transferases. Glycoconjugates of the cell surface are 
thought to play important roles in a variety of biological 
functions, such as cell–cell and cell–substrate inter-
actions, bacterial adhesion, membrane organization, cell 
immunogenicity and protein targeting. For example, 
sialyl-Lewisx (sLex) antigens are the ligands for selectins 
and are involved in the recruitment of leukocytes to 
lymphoid tissues and inﬂ  ammation sites [1].
Glycan structures depend on the cell type, develop-
mental stage and cell diﬀ  erentiation, and are modiﬁ  ed in 
many pathologic states including cancers. Th  e modiﬁ  -
cation of cellular glycosylation is indeed a common 
phenotypic change of cancer cells that mainly aﬀ  ects the 
outer part of glycans, leading to the expression of 
tumour-associated carbohydrate antigens (TACAs). 
Increased β1,6-branching, increased sLex or sialyl-Lewisa 
(sLea) antigens, or the general increase in sialylation are 
commonly observed in N-linked and O-linked glycans of 
carcinoma cells and are associated with grade, invasion, 
metastasis and poor prognosis. Th  ese changes in glyco-
sylation often reﬂ  ect a deregulation of glycosyl  transferase 
expression at the transcriptional level, and several 
examples have shown that glycosyltransferase genes, 
includ ing  ST6GAL1 [2] and MGAT5 [3], are regulated by 
oncogenes.
sLex, s-Lea and sialyl-Th   omsen-nouvelle (sTn) are 
tumour-associated antigens found in breast cancer [4-6]. 
When these antigens are detected at the surface of breast 
carcinoma cells, they are usually associated with a poor 
prognosis and a reduced overall survival of the patients 
[7]. Th  ese glyco  sylation changes mostly result from the 
modiﬁ   cation of the expression of glycosyltransferase 
(GT) genes, and the level of expression of sialyltrans-
ferases has been proposed as a prognostic marker for the 
follow-up of breast cancer patients [8,9].
Several cellular models have been developed in order to 
explain the mechanisms by which carbohydrate antigens 
can reinforce breast cancer progression and aggressive-
ness, showing the implication of TACAs in cell adhesion, 
migration, proliferation and tumour growth [10,11]. 
TACAs such as sTn are also targets for breast cancer 
immunotherapy. Finally, recent data seem to indicate an 
important role of complex gangliosides in breast cancer 
progression and metastasis [12,13]. Th  e present review 
summarizes our current knowledge of glycosylation 
changes that occur in breast cancer and the consequences 
of these changes on disease development and 
aggressive ness.
Defects in mucin-type O-glycosylation
One of the hallmarks of breast adenocarcinomas is the 
over  expression and aberrant localization of membrane-
bound mucins, such as MUC1 and MUC4 [14]. Mucins 
are characterized by a large number of tandem repeated 
domains, rich in serine and threonine, which are 
therefore densely O-glycosylated.
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© 2010 BioMed Central LtdO-glycans expressed by normal breast epithelial cells are 
composed of Core2 structures extended with a linear 
polylactosaminic chain, which can be fucosylated or 
sialylated [15] (Figure 1). Accordingly, a recent study 
reported a prevalence of Lex expression at the apex of 
normal breast epithelia, where MUC1 is also detected [16].
In contrast, breast cancer cell lines express truncated 
O-glycans with shorter polylactosaminic chains and a 
tendency to switch from Core2 O-glycans to sialylated or 
unsialylated Core1 structures (Figure 1) [17]. It has long 
been known that breast cancer tissues contain more sialic 
acid and more sialyltransferase activity [18] than corres-
ponding normal tissues. Breast cancer cells may thus 
express shorter O-glycans due to premature sialylation of 
the polylactosaminic chain blocking further extension, or 
due to truncation of the O-glycans at the core level – 
owing to the sialylation of the Core1 structure or of the 
initial GalNAc, leading to the expression of sialyl-
Th  omsen–Friedenreich (sialyl-T) antigen structures and 
sTn antigen, respectively (Figure 1).
Alternatively, a defect in GTs that are involved in the 
biosynthesis of the O-glycan cores can also lead to the 
incomplete synthesis of the glycans, allowing the expres-
sion of O-linked carbohydrate antigens known as 
Th  omsen–Friedenreich (T or TF) antigen (unsialylated 
Core1) and Th  omsen-nouvelle (Tn) antigen (initial un-
substituted GalNAc) (Figure 1).
Thomsen–Friedenreich antigen
T antigen is the cryptic precursor of Core2 O-glycans, 
which can be unmasked if the cancer cells lose their 
ability to synthesize Core2 (Figure 1). T antigen consists 
of unsialylated Core1 structures (Galβ1-3GalNAcαSer/
Th  r) initially described on glycophorins of red blood 
cells. Th   e galactose residue is crucial for the antigenicity 
since re-sialylation or β-d-galactosidase treatment abro-
gates T-antigen detection [19].
Georg Springer was the pioneer of the study of T antigen 
in breast cancer. Using natural anti-T antisera, he ﬁ  rst 
showed that all breast cancers, but not benign lesions or 
normal mammary gland, expressed the T  antigen [20]. 
Later studies using monoclonal antibodies demonstrated 
the presence of T antigen at a low level in normal 
epithelium or metaplastic lesions of the breast [21].
Lectins such as Arachis hypogea agglutinin/peanut 
lectin (PNA), Amaranthus caudatus lectin or Artocarpus 
integrifolia/jacalin have been extensively used to detect 
T antigen. None of these lectins, however, is exclusively 
speciﬁ   c for the Galβ1-3GalNAc structure. Both A. 
caudatus agglutinin and A. integrifolia agglutinin/jacalin 
are speciﬁ  c for GalNAc when there is no substitution on 
C6 of the saccharide (Figure 2). In contrast, substitution 
on C3 does not impair their binding. Conse  quently both 
A. caudatus agglutinin and A. integrifolia agglutinin/
jacalin can bind to Tn antigen (GalNAcα-Ser/Th  r), T 
antigen (Galβ1-3GalNAcα-Ser/Th  r) and sialyl-T antigen 
(Neu5Acα2-3Galβ1-3GalNacα-Ser/Th  r)  [22,23].
PNA is speciﬁ   c for unsubstituted Gal residues [24]. 
Because of its high reactivity with asialo-glycophorin, 
PNA has been tagged as the anti-T lectin [24]. PNA was 
able to react weakly with healthy tissue while anti-T anti-
sera were not, however, suggesting that PNA speciﬁ  city 
was slightly wider than the sole T carbohydrate. Indeed, 
PNA can bind, albeit with lower aﬃ   nity,  to  terminal 
galac  tose in a variety of glycans including glycolipids 
such as asialo-GM1 [23] or N-acetyl-lactosamine (LacNAc) 
[25]. Studies of T-antigen expression using PNA should 
therefore be treated cautiously, especially in the absence 
of complementary analysis of the O-glycosylation of the 
considered cells or tissues.
In parallel to lectins, mAbs have long been used to 
investigate T-antigen expression in epithelial cancers 
[26]. As for lectins, most mAbs are not strictly speciﬁ  c 
for the sole Galβ1-3GalNAc-Ser/Th   r structure – some of 
them, such as A78-G/A7, cross-reacting with asialo-GM1. 
Other mAbs deﬁ  ne  site-speciﬁ   c T antigens, such as 
BW835 with the VTSA motif in MUC1 tandem repeat. 
Th   e HH8 mAb, as PNA, tolerates further substitution on 
the C6 of the GalNAc leading to Core2 structures [26] 
(Figure 2).
Th   ese subtle diﬀ  erences of speciﬁ  city concur with the 
variability of the detection of T antigen in tumour tissues 
[26,27], and these discrepancies have fuelled debates 
regarding the prognosis value of T-antigen expression in 
breast cancers. PNA staining does not have any prog-
nostic signiﬁ  cance [26], while a more recent study using 
the mAb A78-G/A7 showed a correlation of T-antigen 
expression with a better prognosis [28], opposite to what 
is reported for gastrointestinal, lung or cervix cancers.
A recent study has shown that 98% of the disseminated 
tumour cells in the bone marrow were positively stained 
by a new anti-T antibody [29], suggesting a role for 
T antigen in the metastasis process. Th   is putative role has 
been investigated during the past decade, on the assump-
tion that Galβ1-3GalNAc-R disaccharide could be a good 
ligand for Galectin-3 [30], which has been shown to 
promote breast cancer metastasis by mediating adhesion 
to endothelial cells. Although Galectin-3 seems to be 
involved in breast cancer metastasis through its inter-
action with some cancer-associated O-glycans [31], 
however, the nature of its ligand remains to be clearly 
elucidated via a comprehensive characterization of the 
glycosylation pattern required for this interaction.
To summarize, there is strong evidence showing that 
T antigen is frequently overexpressed in breast cancer, 
suggesting that the changes in O-glycosylation provide 
some advantage to the tumour development. Relation to 
prognosis or metastatic behaviour, however, suﬀ  ers from 
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diﬀ   erent probes – and remains to be unambiguously 
demonstrated.
Thomsen-nouvelle antigen
Tn antigen is the cryptic precursor of the T antigen 
(Core1) that can be unmasked if a cell loses its ability to 
synthesize the Core1 structure (see Figure 1).
Tn (GalNAcα-R) expression on blood cells is respon-
sible for Tn syndrome, which is a rare autoimmune 
haematological disorder [32]. Tn syndrome occurs due to 
mutations in the COSMC gene coding the C1β3GalT-
speciﬁ  c molecular chaperone, leading to a drastic decrease 
of C1β3GalT (T-synthase) activity [33]. Mutations  and 
loss of heterozygosity of COSMC were described in colon 
cancer and melanoma cancer Tn-positive cells, as well as 
in tissues from two Tn-positive cervical cancers [34]. 
Extensive studies of COSMC in epithelial cancers, 
however, showed that these events were rare and could 
only partially explain Tn expression in cancers [35].
A range of GalNAc-speciﬁ   c lectins, including Helix 
pomiata lectin (HPA) and plant lectins from Dolichos 
biﬂ  orus,  Griﬀ  onia  simplicifolia,  Wistaria ﬂ  oribundia, 
Glycine max soybean, Vicia villosa isolectin B4 (VVA) 
and Salvia sclarea agglutinin, can be used to detect Tn 
antigen [32,36]. Th  ese lectins bind to terminal GalNAc 
and therefore react with Tn antigen, but also with 
Forssman antigen (GalNAcα1-3GalNAcβ-R) and to some 
extent with blood group A (GalNAcα1-3[Fucα1-2]Galβ-R) 
or glycolipids [36]. HPA, which has been extensively used 
to study Tn expression in breast cancer [37], has been 
shown by some authors to bind T antigen [36]. Th  ere  is 
also a range of mAbs available to detect Tn antigen [32]. 
Some of them, however, can slightly cross-react with sTn.
Tn antigen was found to be expressed in almost 90% of 
breast cancers while it is barely detected in normal tissue 
Figure 1. Pathways of biosynthesis of O-glycans in normal and cancer breast epithelial cells. All of these transfer reactions are catalysed 
in the Golgi apparatus. Enzymes involved in the pathways are indicated in italic font next to the arrows. Various mechanisms are illustrated by 
which O-glycans expressed in normal cells (bottom left) can be turned down to shorter and sialylated species. First, the enzymes involved in 
extended O-glycans can be downregulated or mutated (downward white arrows) in cancer cells, leading to a decrease or an absence of extended 
structures and revealing previously masked precursors such as T and Tn antigens. Alternatively or concomitantly, overexpression of diverse 
sialyltransferases (upward white arrows) can compete with the enzymes of normal extension and generate truncated sialylated structures (right 
column). This competition can occur at diff  erent levels of the extension pathway and produce the sialylated structures of each precursor (that is, 
sialyl-Thomsen-nouvelle (sTn) antigen, sialyl-Thomsen-Friedenreich (sialyl-T or sialyl-TF) antigen (or sialylated Core1) and sialylated Core2 O-glycans). 
Gal, Galactose, GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine; Neu5Ac, N-acetylneuraminic acid; Fuc, fucose. Linkages (anomery 
and carbons involved) are only indicated the fi  rst time they appear along the pathway. N, various numbers (2 to 10) of repeats of lactosamine units 
(Gal β1-3/4GlcNAc).
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invasive ductal carcinomas (IDC) using a pool of anti-Tn 
antibodies [39] and for ductal carcinoma in situ using 
VVA and G. simplicifolia agglutinin [40]. Using VVA, G. 
simplicifolia agglutinin and 83D4 mAb, other authors 
reported a tendency to lose Tn expression in grade III 
tumours [41]. Using either anti-Tn mAb or VVA, Tn was 
found associated with the Pathological Tumor-Node-
Metastasis (pTNM) tumour stage in IDC [39,42]. Tn 
expression was also associated with decreased overall 
survival using antibodies [35] or HPA [43] and with 
increased risks of recurrence using VVA [42] or HPA [44].
Strikingly, Tn expression was always observed in lymph 
node metastatic cells using either mAb or lectins [39,41] 
with 100% of Tn-positive metastatic cells, while primary 
tumours could exhibit various percentages of cell 
positivity [39,41,42]. Tn expression in primary tumours 
seems consistently associated with lymph node involve-
ment using mAbs [41,42], HPA [43] or VVA [42], and 
even with invasion of lymphatic vessels within the 
primary tumour [42]. Th   is observation strongly suggests 
that Tn antigen may play a role in the mechanism 
involved in lymph node metastasis. Indeed, Danussi and 
colleagues have recently shown that a newly generated 
anti-Tn antibody could block Tn-positive MCF-7 breast 
cancer cell line interaction with lymphatic endothelium 
of the mammary pad in an animal model [45]. A putative 
receptor(s) for Tn antigen in lymphatic cells, however, 
remains to be identiﬁ  ed.
One known receptor for Tn antigen is the macrophage 
galactose-type lectin (MGL), which, in human, is speciﬁ  c 
for GalNAc [46]. MGL is expressed in immature dendritic 
cells and macrophages, and is proposed as an immuno-
modulatory receptor [46]. MGL has been shown to bind 
Tn antigen carried by MUC1 in colon carcinoma cells 
[47], and human immature dendritic cells can uptake 
MUC1-Tn peptide in a MGL-mediated way [48]. Th  e 
MGL–Tn interaction, however, has not yet been 
investigated regarding its possible functional involvement 
in breast cancer development.
Figure 2. Short O-glycans observed in breast epithelial cells during carcinogenesis. Structures of short O-glycans observed in breast epithelial 
cells during carcinogenesis and their binding to Arachis hypogea agglutinin/peanut lectin (PNA) lectin or HH8 mAb, and to Amaranthus caudatus 
agglutinin (ACA) or Artocarpus integrifolia agglutinin/jacalin (AIA). T or TF, Thomsen–Friedenreich; Tn, Thomsen-nouvelle.
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Tn antigen can be sialylated at the C6 position of GalNAc, 
resulting in the disaccharide Neu5Acα2-6GalNAc-R (sTn). 
STn is absent in normal healthy tissues but can be 
detected at various frequencies in almost all kinds of 
carcinomas [49].
ST6GalNAc I is the enzyme catalysing the transfer of 
sialic acid onto GalNAc in vivo [50]. It has been proposed 
that  COSMC mutation was necessary to provide the Tn 
acceptor substrate for ST6GalNAc I to synthesize sTn 
antigen [34]. Transfection of ST6GalNAc I cDNA, how  ever, 
has been shown to be suﬃ   cient to induce sTn expression in 
various breast cancer cell lines expressing Core1 and Core2 
glycans [11,50,51], proving that ST6GalNAc I can compete 
with active Core1 β1,3-galacto  syl  transferase.
Several mAbs have been raised against sTn antigen 
using various immunogens, leading to subtle diﬀ  erences 
in the way they recognize sTn [49]. Th  e  most  commonly 
used mAbs in breast cancer investigations are B72.3, 
TKH2 and HB-STn1. B72.3 appeared to be speciﬁ  c for 
clustered sTn but also cross-reacts with Tn clusters 
[52,53]. In contrast, TKH2 reacts more strongly to mono-
meric sTn conjugated to keyhole limpet hemocyanin 
(STn-KLH) than B72.3 [54].
Th  e reported occurrence of sTn expression in breast 
cancer is highly variable. It is commonly accepted that at 
least 25 to 30% of breast cancers are sTn-positive [51]. 
Th   e reported ranges are 20 to 80% using B72.3 and 30 to 
60% using HB-STn1 [49], and correlation with known 
prognosis markers varies from one study to another. 
Corre  lation with a decreased overall survival seems to be 
the more consistent correlation through the literature. 
Kinney and colleagues proposed that sTn was an 
indepen  dent predictor of poor prognosis of breast 
cancers [55]. Miles and colleagues, however, reported a 
signiﬁ  cant correlation of sTn expression with the decreased 
survival in the restricted node-positive patient group [7], 
whereas Leivonen and colleagues limited the association 
to the short-term prognosis [56].
Induction of sTn expression by transfection of the breast 
cancer cell line with ST6GalNAc I cDNA decreased the 
adhesion of cells to matrix proteins, and increased mobility 
and tumour growth in a xenograft model [10,11,50]. Th  ese 
observations are in accordance with a more aggressive 
phenotype of cancer cell that is usually associated with sTn 
expression but remain to be eluci  dated at the molecular 
level. Of the various sTn-positive proteins present in these 
transfected cell lines, only four have been identiﬁ  ed: 
MUC1 and CD44 in human [10], and integrin β1 [57] and 
osteopontin [58] in mouse. All of these molecules have 
described functions in adhesion and/or migration, and it 
has been suggested that the modiﬁ   cation of their O-
glycosylation may inﬂ  uence this function and the mobility 
of the cancer cells.
Lewis antigens in breast cancer
Structure and biosynthesis of Lewis antigens
Th   e histoblood group Lewis antigens are found in most 
human epithelial tissues, where they are expressed at the 
terminal part of glycolipid and glycoprotein glycan chains 
[59]. Th   ese antigens derive from the substitution of type 
1 (Galβ1-3GlcNAc) or type 2 (Galβ1-4GlcNAc) 
disaccharide sequences by fucose and sialic acid residues 
(Figure 3). Lea, Leb and sLea derive from type 1 sequences, 
and Lex, Ley and sLex derive from type 2. In healthy 
individuals, type 1 (Lea and Leb) antigens are widely 
expressed, while type 2 (Lex and Ley) antigens are only 
expressed at relatively low levels. Th  e biosynthesis of 
these antigens requires speciﬁ  c fucosyl  transferases and 
sialyltransferases (Table 1).
Th  e GlcNAc α1,4-fucosylation of type 1 disaccharide 
generates Lea antigen, whereas the α1,3-fucosylation of 
type 2 gives Lex (Figure 3).Th  e fucosyltransferases FucT 
III, FucT IV, FucT VI and FucT IX catalyse the transfer of 
a fucose residue onto GlcNAc of type 1 or type 2 
disaccharides, thus synthesizing α1,3-fucosylated and, in 
the case of FucT III, α1,4-fucosylated glycans [60-62]. 
FucT III is the only enzyme responsible for the synthesis 
of Lea and sLea in vivo and is called the Lewis enzyme. 
Th  e fucosyltransferases FucT I and FucT II are respon-
sible for the Gal α1,2-fucosylation of Lea or Lex, 
generating Leb or Ley antigens, respectively (Figure 3). 
FucT I (H enzyme) preferentially fucosylates type 1, 
whereas FucT II (Se enzyme) determines the expression 
of H-type 2 (Fucα1-2Galβ1-4GlcNAc) and Ley antigens.
Th   e biosynthesis of sialylated Lewis antigens (sLea and 
sLex) requires ﬁ   rst the α2,3-sialylation of Gal prior to 
α1,3/4-fucosylation. ST3Gal III [63], preferentially acting 
on type 1 rather than on type 2 disaccharides, is involved 
in sLea synthesis. ST3Gal IV and ST3Gal VI mainly act 
on type 2 disaccharide, leading to the biosynthesis of sLex 
[64], but both also share acceptor speciﬁ  city with ST3Gal 
III. For the subsequent fucosylation, FucT III is the main 
enzyme involved in the biosynthesis of sLea [65], whereas 
FucT VII [62,66] shows a restricted substrate speciﬁ  city 
since it can form only sLex [67].
Overexpression of Lewis antigens in breast cancer
Th   e expression of sialyl-Lewis antigens is usually altered 
in breast cancer. Normal breast commonly expresses Lex, 
mainly in the apical part of cell ducts, together with 
MUC1. sLex and sLey epitopes may also be sometimes 
detected in normal breast, but with a low intensity [16]. 
On the contrary, sLea and sLex expression is found to be 
increased in breast cancer tissues, including primary 
breast carcinoma lesions [68]. Furthermore, levels of 
expression of sLex are higher in patients who had distant 
metastasis compared with patients presenting nonmeta-
static cancers [69]. Th   e expression of sialyl-Lewis 
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invasive carcinomas without metastases and is high in 
primary carcinoma with lymph node metastases, show-
ing a good correlation with the metastatic risk in breast 
cancer patients [70]. Immuno  histochemistry of breast 
cancer tissue suggests that sLex expression is an indepen-
dent prognostic indicator of survival regardless of the size 
of the primary tumour and lymph node involvement [71].
RNA analysis of tumours indicated that FucT VI 
expression correlates with the levels of sLex. Furthermore, 
transfection of the FUT6 gene into MCF-7 breast cancer 
cells showed that FucT VI is responsible for an 
enhancement of sLex expression [72]. Th  e  downregulation 
of ST3Gal IV increased MCF-7 cell adhesion and 
decreased MDA-MB-231 cell migration, suggesting that 
α2,3-sialylation played a crucial role in the adhesion and 
tumour metastases [73]. In parallel, the level of ST3Gal III 
expression is associated with axillary lymph node involve-
ment and a reduced overall survival of patients [8,9].
A general reduced expression of type 1 carbohydrate 
antigens and increased expression of type 2 antigens in 
breast cancer tissues has also been reported [4,6], and the 
relative expression of type 2 carbohydrate antigens seems 
capable of serving as a prognostic factor. As much as 80%   
Figure 3. Biosynthesis of Lewis antigens. Lewis antigens derive from the substitution of type 1 (Galβ1-3GlcNAc) or type 2 (Galβ1-4GlcNAc) 
disaccharide sequences by fucose and sialic acid residues. Name of the antigen is indicated next to the glycan structure. Names of the main 
enzymes involved in the biosynthetic pathways are indicated in italics. Arrows, antigens and enzymes altered in breast cancers.
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Fucα1-2
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Table 1. Fucosyltransferases and sialyltransferases potentially involved in biosynthesis of histoblood group Lewis 
antigens in breast tissues
Gene name  Common name  Accession number  Main acceptor substrate
α1,2-Fucosyltransferases  
 FUT1 FucT  I  NM_000148  Galβ1-3[Fucα1-4]0-1GlcNAc
 FUT2 FucT  II  NM_000511  Galβ1-4[Fucα1-3]0-1GlcNAc
α1,3/4-Fucosyltransferases  
 FUT3 FucT  III  NM_000149  Galβ1-3/4GlcNAc
 FUT6 FucT  VI  NM_000150  Galβ1-4GlcNAc
 FUT7 FucT  VII  NM_004479  NeuAcα2-3Galβ1-4GlcNAc
 FUT9 FucT  IX  NM_006581  Galβ1-4GlcNAc
α2,3-Sialyltransferases  
 ST3GAL3 ST3Gal  III  NM_174972  Galβ1-3GlcNAc
 ST3GAL4 ST3Gal  IV  NM_006278  Galβ1-4GlcNAc
 ST3GAL6 ST3Gal  VI  NM_006100  Galβ1-4GlcNAc
The acceptor monosaccharide is indicated in bold.
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which correlates with the degree of malignancy and 
invasiveness [74].
Th  e expression level of sLex is also increased in the 
serum of patients with advanced breast cancer [69,75] and 
is therefore a good candidate as a diagnosis marker. In 
combination with serum CA15-3, the most commonly 
used breast cancer marker, the measurement of serum sLex 
improves monitoring – for 78.5% of detected meta  static 
breast cancer, compared with 61.5% when CA15-3 is used 
alone [76].
Th  e Ley antigen is also overexpressed in 60 to 90% of 
cancer of epithelial origin, including breast cancer [77]. A 
clinical study showed that high expression of Ley corre-
lated with high grade and poor prognosis, and signiﬁ  -
cantly decreased patient survival in lymph node-negative 
breast carcinoma [78]. Showing restricted expression on 
epithelial surfaces in normal tissues, Ley also constitutes a 
good candidate for cancer immunotherapy [79].
Implication of sialyl-Lewis antigens in metastasis
Th   e expression of sLex on leukocytes contributes to their 
function in the inﬂ   ammatory response via interaction 
with E-selectin expressed on endothelial cells. By expos-
ing sLex at the cell surface, malignant cells can use a 
similar strategy for the extravasation  from the blood 
circulation and metastasis, targeting tissues where E-
selectin is highly expressed.
Both P-selectin and E-selectin expression is signiﬁ  -
cantly enhanced on endothelial cells of breast cancer 
patients [68], consistent with the proposal that sLex 
binding to selectins aids cancer cell metastasis. A high 
tumour-associated ST3Gal III expression and a high E-
selectin serum concentration were associated with a bad 
prognosis for relapse-free survival and overall survival in 
patients with node-negative breast cancer [8]. In both 
canine mammary carcinoma and the human inﬂ  am-
matory breast cancer model, the cellular expression of E-
cadherin and sLex are inversely corre  lated, suggesting a 
biologically coordinated mechanism of E-cadherin and 
sLex expression essential for tumour establishment and 
metastatic progression [80].
Gangliosides in breast cancer
Structure and biosynthesis of gangliosides
Gangliosides are expressed at the plasma membrane of 
cells, especially in developing tissues and the adult central 
nervous system. Gangliosides structurally and biosyn-
thetically derive from lactosylceramide (LacCer), and 
additional sugar residues – including sialic acid, N-acetyl-
galactosamine and galactose – are transferred in a step-
wise manner by a series of speciﬁ  c GTs [81] (Figure 4). 
GM3, GD3 and GT3 are the starting points for the bio-
synthesis of a-series, b-series and c-series ganglio  sides, 
respectively (Figure 4). Th  e relative amounts of these 
glycosphingolipids deter  mine the amount of complex 
gangliosides of each series. Th  e amount of complex gan-
glio  sides is therefore depen  dent on the level of expression 
and activity of several GTs, including GM3 synthase 
(ST3Gal V), GD3 synthase (ST8Sia I), GT3 synthase (ST8Sia 
V) and GM2/D2 synthase (β1,4-GalNAc T1) (Table 2).
Overexpression or neo-expression of gangliosides in 
breast cancer
Th  e neo-expression of gangliosides has been usually 
demonstrated in a variety of cancers – especially in 
neuro  ectoderm-derivated tumours, in which they play a 
key role in invasion and metastasis. Breast tumour tissues 
were shown to be distinct from normal mammary tissues 
in terms of ganglioside composition. Th  e gangliosides 
GM3, GD3 and the derivatives 9-O-acetyl-GD3 (CDw60 
antigen) and 9-O-acetyl-GT3, which show a very restricted 
expression in normal breast tissues, are overexpressed in 
about 50% of IDC [82].
Th  e  N-glycolyl-GM3 is also detected in IDC, with 100% 
eﬃ   ciency in primary tumours for women diagnosed with 
stage II breast cancer [82,83]. Neu5Gc is normally absent 
in human due to the irreversible inactivation of the 
CMAH gene encoding the CMP-Neu5Ac hydroxylase. 
Th   e lack of the enzyme responsible for the conversion of 
CMP-Neu5Ac in CMP-Neu5Gc results in the total 
absence of Neu5Gc in healthy human tissues. On the 
contrary, Neu5Gc was shown to be expressed on glyco-
proteins and gangliosides in melanoma, colon, retino-
blastoma and breast cancers.
Th   e expression of GTs implicated in ganglioside 
biosynthesis can be also altered in breast cancer tumours. 
Two clinical studies have shown that the GD3 synthase 
(ST8Sia I) displayed higher expression among oestrogen 
receptor-negative breast cancer tumours [84]. ST8SIA1 
overexpression was associated with poor pathohisto  lo-
gical grading in oestrogen receptor-negative tumours and 
lower survival of patients [85]. In contrast, a better 
prognosis for oestrogen receptor-positive samples with 
high expression of ST8SIA1 was noticed [85].
It has been shown that silencing of GM3 synthase in 
mammary murine 4T1 cells signiﬁ  cantly inhibited cell 
migration, invasion and anchorage-independent growth 
in vitro, as well as lung metastasis in vivo. In parallel, 
overexpression of GM3 synthase in nonmetastatic 67NR 
cells signiﬁ  cantly restores the malignant phenotype [86]. 
We have recently demonstrated that overexpression of 
GD3 synthase in MDA-MB-231 cells is associated with 
increased proliferation, especially in the absence of 
serum or exogenous growth factors [13]. GD3 synthase-
overexpressing cells bypass the need of serum for cell 
growth by the activation of Erk/MAPK, PI3K/Akt and 
SAPK/JNK pathways (unpublished results). Th  ese data 
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contribute to increasing the malignant properties of 
breast cancer cells by mediating cell proliferation and 
migration. Recently, the role of ST6GalNAc V, a sialyl-
transferase involved in the biosynthesis of α-series 
gangliosides, in breast cancer metastasis to the brain has 
been clearly demonstrated. Normally restricted to the 
brain, the expression of ST6GalNAc V enhances the 
adhesion of breast cancer cells to brain endothelium and 
their passage through the blood–brain barrier, high-
lighting the role of cell surface glycosylation in organ-
speciﬁ  c metastatic interactions [12].
Future perspectives for therapy
From the data summarized above, it appears that a 
limited number of TACAs are expressed in breast cancer 
and associated with restricted histopathological markers 
such as the oestrogen receptor status of tumours (Table 3). 
Breast cancer cells express truncated Core1-based 
O-glycans, including T, Tn and sTn antigens. Th  e 
expression of sialyl-Lewis antigens is also altered in 
breast carcinoma with a good correlation with metastatic 
risk, and complex gangliosides are overexpressed in IDC.
Although some TACAs have been shown as strong 
markers of a poor prognosis (for example, sLex or sTn), 
they have not yet reached the clinic. Indeed, the strongest 
marker of prognosis in breast cancer remains the 
invasion of the lymph nodes determined during surgery. 
Unless another marker proves to be of superior quality or 
independent of lymph node involvement, it is very 
unlikely to be useful for clinic application. As TACAs are 
more or less associated with lymph node invasion and/or 
restricted to speciﬁ   c groups of patients, their use as 
prognosis markers appears rather limited. However, since 
TACAs seem to be functionally involved in cancer 
progression, one of their most promising uses in the 
future remains being targets for treatments designed for 
speciﬁ  c groups of patients.
Figure 4. Biosynthesis of gangliosides. The action of ST3Gal V (GM3 synthase), ST8Sia I (GD3 synthase) and ST8Sia V (GT3 synthase) leads to the 
biosynthesis of the precursor of a-series, b-series and c-series gangliosides, respectively. The o-series gangliosides are directly synthesized from 
lactosylceramide (LacCer). Elongation of complex gangliosides is performed by the sequential action of N-acetyl-galactosaminyltransferase 
(β4-GalNAc T1), galactosyltransferase (β3-GalT4) and sialyltransferases (ST3Gal I, ST3Gal II and ST8Sia V).
LacCer
ST3Gal V ST8 Sia I ST8Sia V
Cer
α α3
β4
Cer
α3
β4
Cer
α3
β4
Cer
β4
LacCer
GM3
GD3
GT3
α8
α8
α8
β4-GalNAc T1
Cer
α3
β4 β4
Cer
α3
β4 β4
Cer
α3
β4 β4
Cer
β4 β4
GM2
GD2
G
GA2
α8
α8
α8
GT2
β3-GalT4
Cer
α3
β4 β4 β3
Cer
α3
β4 β4 β3
Cer
α3
β4 β4 β3
Cer
β4 β4 β3
GM1a
GD1b
G
GA1
α8
α8
α8
GT1c
o-Series a-Series b-Series c-Series
ST3 Gal I/II
ST8Sia V
o-Series a-Series b-Series c-Series
Glc GalNAc Neu5Ac Gal
Cazet et al. Breast Cancer Research 2010, 12:204 
http://breast-cancer-research.com/content/12/3/204
Page 8 of 13Diﬀ  erent methods can take advantage of TACA expres-
sion to treat breast cancer, such as blocking their bio-
synthesis or biological function, or using them as 
molecular targets in immunotherapy. Blocking the bio-
synthesis of glycans using chemical inhibitors has been 
shown to change the phenotype of breast cancer cells in 
culture, making them less aggressive [87,88]. Such an 
approach, however, is diﬃ   cult to adapt to human therapy 
because both healthy and diseased cells are using their 
glycans in a variety of functions. Th   ere are high risks that 
detrimental eﬀ   ects of a chemical inhibitor on healthy 
cells would counterbalance or avoid the beneﬁ  cial eﬀ  ect 
of the molecule on cancer cells. In order to develop 
further, this ﬁ  eld will have to await improvement in the 
Table 2. Main glycosyltransferases involved in biosynthesis of gangliosides
Gene name  Common name  Accession number  Main acceptor substrate
Glucosyltransferase  
 UGCG  GlcCer synthase  NM 003358.1  Ceramide (Cer)
Galactosyltransferases  
 B4GALT6 LacCer  synthase  NM_004775  Glcα1-Cer
 B3GALT4 β3-GalT4  NM_003782.3  GalNAcβ1-4[NeuAc0-3]Galβ1-4Glcα1-Cer
N-Acetyl-galactosaminyltransferase  
 B4GALNACT1 G M2, GD2, GT2 synthase  NM_001478.2  [NeuAc0-3]Galβ1-4Glcα1-Cer
Sialyltransferases  
 ST3GAL1 ST3Gal  I  NM_003033.3  Galβ1-3GalNAcβ1-4[NeuAc0-3]Galβ1-4Glcα1-Cer
 ST3GAL2 ST3Gal  II  NM_006927.3  Galβ1-3GalNAcβ1-4[NeuAc0-3]Galβ1-4Glcα1-Cer
 ST3GAL5 ST3Gal  V  NM_003896.3  Galβ1-4Glcα1-Cer
 ST6GALNAC5 ST6GalNAc  V  NM_030965.1  NeuAcα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glcα1-Cer
 ST8SIA1 ST8Sia  I  NM_003034.3  NeuAcα2-3Galβ1-4Glcα1-Cer
 ST8Sia5 ST8Sia  V NM_013305.4  NeuAcα2-8NeuAcα2-3Galβ1-4Glcα1-Cer
The acceptor monosaccharide is indicated in bold.
Table 3. Main tumour-associated carbohydrate antigens expressed in breast carcinomas
TACA DCIS  IDC  Altered  pathway  Comments
Mucin-type antigens    
 Thomsen-nouvelle  High  High  COSMC mutation, decrease in C1β3GalT   Expressed in almost 90% of breast
       activity  cancers
  Thomsen–Friedenreich  ND  High  Decrease in Core2 β6-GlcNAc-T expression, 
        decrease in Core1 sialylation 
  Sialyl-Thomsen-nouvelle  ND  High  Increase in ST6GalNAc I expression, decrease   25 to 30% of breast cancers, correlated
        in Core2 β6-GlcNAc-T expression, alteration   with a decreased survival in
       of  COSMC function  node-positive patients
Lewis antigens      
 Sialyl-Lewisx  Weak  High  Increased expression of FucT (FucT VI and   Higher in metastatic compared with
       FucT  VII)  nonmetastatic  cancers
 Sialyl-Lewisa  Weak  High  Increased expression of FucT (FucT III) 
 Lewisy  Low  High  Increased expression of FucT  Overexpressed in 60 to 90% of breast 
         cancer
Gangliosides      
 G M3  ND  Increased  Increased expression of ST3Gal V  2.8-fold compared with normal tissue
 G D3  ND  Increased  Increased expression of ST8Sia I  1.7-fold compared with normal tissue
 9-O-acetyl-GD3  ND  Neo-expression  Increase of sialic acid acetylation 
 9-O-acetyl-GT3  ND  Neo-expression  Increase of sialic acid acetylation 
  N-glycolyl-GM3  ND  65 to 70%  Unknown  100% in stage II primary tumours
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ND, not determined; TACA, tumour-associated carbohydrate antigen.
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booming nanotechnologies [89].
Alternatively, one may consider speciﬁ  cally altering the 
expression of GTs involved in TACA biosynthesis. Little 
is still known about the molecular mechanisms leading to 
aberrant expression of GTs in cancer. Gain or loss of GT 
expression could be attributed to loss of chromosomal 
integrity often observed in cancers, leading to duplica-
tion, deletion or transposition of chromosomal segments 
involving glycosyltransferase genes. As an example, 
elevated ST6Gal I expression in murine W16 cells has 
been shown to be the result of DNA rearrangement in 
the  st6gal1 locus resulting from the transposition of a 
retroviral-like transposable element upstream of the 
st6gal1 ORF [90]. Changes of gene expression do not 
always reﬂ   ect genomic rearrangements, however, as 
comparison of the Comparative Genomic Hybridization 
Array and the RNA microarray do not always show 
absolute correlation. Expression of GT genes is often 
regulated at the trans  criptional level [91], and several 
examples have shown that GT genes, including ST6GAL1 
[2] and MGAT5 [3], can be regulated by oncogenes. Only 
a limited number of promoters of GT genes have been 
characterized [91], and this ﬁ  eld is in need of further data 
in order to under  stand which factors of transcription, 
signalling pathways and, eventually, membrane receptors 
are involved in this cancer-speciﬁ   c deregulation. Th  e 
knowledge of the intracellular molecular mechanisms 
regulating the expression of GTs might open new options 
to speciﬁ  cally impair TACA expression in cancer cells.
Functions of TACAs often involve interaction with 
glycan-speciﬁ  c receptors, such as selectins with sialyl-
Lewis antigens. Attempts can be made to block this inter-
action, by masking either the glycans or its receptor. 
Several studies have shown that masking T antigens with 
speciﬁ  c peptides [92] or mAbs [93] can inhibit interaction 
of breast cancer cells with the endothelium and protect 
from metastasis. One advantage of this approach is that 
the lectin(s) recognizing the TACA does not need to be 
identiﬁ   ed to block the interaction. Some limitations 
remain, however, such as the risk to induce unwanted 
physiological responses triggered by the same type of 
interactions (or loss of interaction), or the clinical 
viability of these compounds in terms of toxicity, body 
clearance or administration.
Active immunotherapy has been thoroughly investi-
gated during the past 40 years as an alternative approach 
for cancer treatment. As glycans are naturally highly 
immuno  genic, they have been extensively used for the 
design of immunotherapy strategies against breast 
cancer.
As early as in 1977, Springer and collaborators attemp-
ted to immunize patients with desialylated autologous 
red blood cells, in order to trigger a response to T 
antigen. He reported a signiﬁ  cantly improved 5-year sur-
vival (100%) and 10-year survival (44%) compared with 
the nonimmunized population [38]. Although of small 
scale and somewhat unorthodox, this study paved the 
way for further development of anti-TACA vaccines.
Ganglioside-based anti-idiotype vaccines focusing on 
N-glycolyl-GM3 have been developed for speciﬁ  c active 
immunotherapy against breast cancer [94]. Th  e 1E10 
mAb (Racotumomab) is an anti-idiotype vaccine to P3 
mAb, which recognized Neu5Gc-GM3. Vaccination with 
1E10 of BALB/c mice challenged with the murine F3II 
mammary carcinoma leads to breast tumour growth 
suppression and a decrease of lung metastasis [95]. 
Moreover, the anti-tumour eﬀ  ect of 1E10 is enhanced by 
combination with a low-dose of cyclophosphamide [96]. 
Results of phase I clinical trials have shown that 1E10 
vaccine was relatively well tolerated and able to produce a 
speciﬁ  c response against Neu5Gc-containing gangliosides 
in high-risk (stage III) or metastatic breast cancer [97,98].
Clustered sTn haptens conjugated to keyhole limpet 
hemocyanin (Th   eratope™; Biomira, Edmonton, AB, 
Canada) have also been used to immunize breast cancer 
patients [99]. Although the results of the ﬁ  rst phase III 
clinical trial failed to show signiﬁ  cant beneﬁ  t, it has to be 
mentioned that patients were never screened for 
expression of sTn antigen in the tumours. Th  e lack of 
signiﬁ  cant beneﬁ  t for the total population could therefore 
be explained by the low repre  sentation of patients 
presenting sTn-positive tumours (25 to 30%). Recently, 
we clearly demonstrated that Th  eratope™  induced 
tumour protection in a relevant murine model. Th  e 
protection was dependent on both the presence of the 
sTn antigen in the tumour and the anti-sTn antibodies 
raised by immunization. Interestingly anti-sTn antibodies 
were able to recognize a wide range of sTn-positive 
proteins expressed by mammary carci  nomas, suggesting 
that multi-targeting of the response was important to 
induce tumour protection [58].
Despite decades of research and evident proofs of 
concept in favour of anti-TACA cancer vaccines, one has 
to acknowledge that none of them have reached the 
clinic. One possible method of improvement is a better 
deﬁ  nition of patients who are most susceptible to beneﬁ  t 
from the designed treatment. As TACAs are expressed in 
distinguishable groups of patients based on immuno-
histology or gene proﬁ  ling expression, one may therefore 
consider personalizing the treatment according to 
expression of putative targets. Another way is to design 
multi-epitope targeting vaccines to cover a variety of 
targets found in diﬀ   erent patient populations and to 
possibly trigger multi-antigenic response in each of the 
patients. Glycopeptide dendrimers have been developed 
to present simultaneously up to six diﬀ  erent  antigens 
(Tn, T, Globo H, GM2, Ley, and MUC1-Tn antigens) and 
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multi-antigenic responses with mono-antigenic res-
ponses [100].
As the future of breast cancer treatment lies in a 
combination of patient-tailored and multi-targeting 
strate  gies, we believe that TACAs – because of their 
proﬁ  le of expression and their proaggressive function – 
will be considered potent molecular targets.
Abbreviations
C1β3GalT, Core1 β1,3-galactosyltransferase (EC 2.4.1.122); GT, 
glycosyltransferase; HPA, Helix pomiata agglutinin; IDC, invasive ductal 
carcinoma; Le, Lewis; mAb, monoclonal antibody; MGL, macrophage 
galactose-type lectin; ORF, open reading frame; PNA, Arachis hypogea 
agglutinin; sLe, sialyl-Lewis; sTn, sialyl-Thomsen-nouvelle; T, Thomsen-
Friedenreich; TACA, tumour-associated carbohydrate antigen; Tn, Thomsen-
nouvelle; VVA, Vicia villosa agglutinin isolectin B4.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The present work was supported by the University of Sciences and 
Technologies of Lille, the Association pour la Recherche sur le Cancer (grant 
numbers 7936 and 5023), La Ligue régionale contre le Cancer and the PAI 
Hubert Curien France-Korea STAR.
Author details
1Structural and Functional Glycobiology Unit, UMR CNRS 8576, University of 
Sciences and Technologies of Lille, 59655 Villeneuve d’Ascq, France. 2Université 
Lille Nord de France, F-59000 Lille, France. 3Breast Cancer Biology Group, 
Research Oncology, King’s College London, London SE1 9RT, UK.
Published: 8 June 2010
References
1. Varki  A:  Selectin ligands. Proc Natl Acad Sci USA 1994, 91:7390-7397.
2.  Le Marer N, Laudet V, Svensson EC, Cazlaris H, Van Hille B, Lagrou C, Stehelin 
D, Montreuil J, Verbert A, Delannoy P: The c-Ha-ras oncogene induces 
increased expression of beta-galactoside alpha-2, 6-sialyltransferase in rat 
fi  broblast (FR3T3) cells. Glycobiology 1992, 2:49-56.
3.  Buckhaults P, Chen L, Fregien N, Pierce M: Transcriptional regulation of 
N-acetylglucosaminyltransferase V by the src oncogene. J Biol Chem 1997, 
272:19575-19581.
4.  Narita T, Funahashi H, Satoh Y, Watanabe T, Sakamoto J, Takagi H: Association 
of expression of blood group-related carbohydrate antigens with 
prognosis in breast cancer. Cancer 1993, 71:3044-3053.
5.  Soares R, Marinho A, Schmitt F: Expression of sialyl-Tn in breast cancer. 
Correlation with prognostic parameters. Pathol Res Pract 1996, 
192:1181-1186.
6.  Ura Y, Dion AS, Williams CJ, Olsen BD, Redfi  eld ES, Ishida M, Herlyn M, Major 
PP: Quantitative dot blot analyses of blood-group-related antigens in 
paired normal and malignant human breast tissues. Int J Cancer 1992, 
50:57-63.
7.  Miles DW, Happerfi  eld LC, Smith P, Gillibrand R, Bobrow LG, Gregory WM, 
Rubens RD: Expression of sialyl-Tn predicts the eff  ect of adjuvant 
chemotherapy in node-positive breast cancer. Br J Cancer 1994, 
70:1272-1275.
8.  Hebbar M, Krzewinski-Recchi MA, Hornez L, Verdiere A, Harduin-Lepers A, 
Bonneterre J, Delannoy P, Peyrat JP: Prognostic value of tumoral 
sialyltransferase expression and circulating E-selectin concentrations in 
node-negative breast cancer patients. Int J Biol Markers 2003, 18:116-122.
9.  Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P: 
Multiplex reverse transcription polymerase chain reaction assessment of 
sialyltransferase expression in human breast cancer. Cancer Res 1998, 
58:4066-4070.
10.  Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-
Edouart AS, Hanisch FG, Delannoy P, Le Bourhis X: ST6GalNAc I expression in 
MDA-MB-231 breast cancer cells greatly modifi  es their O-glycosylation 
pattern and enhances their tumourigenicity. Glycobiology 2006, 16:54-64.
11.  Julien S, Lagadec C, Krzewinski-Recchi MA, Courtand G, Le Bourhis X, 
Delannoy P: Stable expression of sialyl-Tn antigen in T47-D cells induces a 
decrease of cell adhesion and an increase of cell migration. Breast Cancer 
Res Treat 2005, 90:77-84.
12.  Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de 
Vijver MJ, Gerald WL, Foekens JA, Massagué J: Genes that mediate breast 
cancer metastasis to the brain. Nature 2009, 459:1005-1009.
13.  Cazet A, Groux-Degroote S, Teylaert B, Kwon KM, Lehoux S, Slomianny C, Kim 
CH, Le Bourhis X, Delannoy P: GD3 synthase overexpression enhances 
proliferation and migration of MDA-MB-231 breast cancer cells. Biol Chem 
2009, 390:601-609.
14.  Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson 
JF, Ellis IO: Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and 
MUC6) and their prognostic signifi  cance in human breast cancer. Mod 
Pathol 2005, 18:1295-1304.
15.  Hanisch FG, Uhlenbruck G, Peter-Katalinic J, Egge H, Dabrowski J, Dabrowski 
U: Structures of neutral O-linked polylactosaminoglycans on human skim 
milk mucins. A novel type of linearly extended poly-N-acetyllactosamine 
backbones with Gal beta(1-4)GlcNAc beta(1-6) repeating units. J Biol Chem 
1989, 264:872-883.
16.  Croce MV, Isla-Larrain M, Rabassa ME, Demichelis S, Colussi AG, Crespo M, 
Lacunza E, Segal-Eiras A: Lewis x is highly expressed in normal tissues: 
a comparative immunohistochemical study and literature revision. Pathol 
Oncol Res 2007, 13:130-138.
17.  Muller S, Hanisch FG: Recombinant MUC1 probe authentically refl  ects 
cell-specifi  c O-glycosylation profi  les of endogenous breast cancer mucin. 
High density and prevalent core 2-based glycosylation. J Biol Chem 2002, 
277:26103-26112.
18.  Abecassis J, Collard R, Eber M, Pusel J, Fricker JP, Methlin G: Proteinases and 
sialyltransferase in human breast tumors. Int J Cancer 1984, 33:821-824.
19. Springer  GF:  T and Tn, general carcinoma autoantigens. Science 1984, 
224:1198-1206.
20.  Springer GF, Desai PR, Murthy MS, Scanlon EF: Human carcinoma-associated 
precursor antigens of the NM blood group system. J Surg Oncol 1979, 
11:95-106.
21.  Schmitt FC, Figueiredo P, Lacerda M: Simple mucin-type carbohydrate 
antigens (T, sialosyl-T, Tn and sialosyl-Tn) in breast carcinogenesis. Virchows 
Arch 1995, 427:251-258.
22.  Tachibana K, Nakamura S, Wang H, Iwasaki H, Maebara K, Cheng L, 
Hirabayashi J, Narimatsu H: Elucidation of binding specifi  city of Jacalin 
toward O-glycosylated peptides: quantitative analysis by frontal affi   nity 
chromatography. Glycobiology 2006, 16:46-53.
23.  Wu AM, Wu JH, Yang Z, Singh T, Goldstein IJ, Sharon N: Diff  erential 
contributions of recognition factors of two plant lectins, Amaranthus 
caudatus lectin and Arachis hypogea agglutinin, reacting with Thomsen–
Friedenreich disaccharide (Galβ1-3GalNAcα1-Ser/Thr). Biochimie 2008, 
90:1769-1780.
24.  Lotan R, Skutelsky E, Danon D, Sharon N: The purifi  cation, composition, and 
specifi  city of the anti-T lectin from peanut (Arachis hypogaea). J Biol Chem 
1975, 250:8518-8523.
25.  Pereira ME, Kabat EA, Lotan R, Sharon N: Immunochemical studies on the 
specifi  city of the peanut (Arachis hypogaea) agglutinin. Carbohydr Res 1976, 
51:107-118.
26.  Hanisch FG, Baldus SE: The Thomsen–Friedenreich (TF) antigen: a critical 
review on the structural, biosynthetic and histochemical aspects of a 
pancarcinoma-associated antigen. Histol Histopathol 1997, 12:263-281.
27.  Cao Y, Stosiek P, Springer GF, Karsten U: Thomsen–Friedenreich-related 
carbohydrate antigens in normal adult human tissues: a systematic and 
comparative study. Histochem Cell Biol 1996, 106:197-207.
28.  Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Krajewski S, 
Sommer H, Friese K: Prognostic impact of Thomsen–Friedenreich tumor 
antigen and disseminated tumor cells in the bone marrow of breast 
cancer patients. Breast Cancer Res Treat 2007, 101:17-25.
29.  Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Sommer H, 
Friese K: Characterisation of disseminated tumor cells in the bone marrow 
of breast cancer patients by the Thomsen–Friedenreich tumor antigen. 
Histochem Cell Biol 2005, 123:631-637.
30.  Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher 
SL, Pienta KJ, Quinn TP: Intravascular metastatic cancer cell homotypic 
aggregation at the sites of primary attachment to the endothelium. 
Cazet et al. Breast Cancer Research 2010, 12:204 
http://breast-cancer-research.com/content/12/3/204
Page 11 of 13Cancer Res 2003, 63:3805-3811.
31.  Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, Gerasimenko 
OV, Hilkens J, Hirabayashi J, Kasai K, Rhodes JM: Galectin-3 interaction with 
Thomsen–Friedenreich disaccharide on cancer-associated MUC1 causes 
increased cancer cell endothelial adhesion. J Biol Chem 2007, 282:773-781.
32. Berger  EG:  Tn-syndrome. Biochim Biophys Acta 1999, 1455:255-268.
33.  Ju T, Cummings RD: Protein glycosylation: chaperone mutation in Tn 
syndrome. Nature 2005, 437:1252.
34.  Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia 
JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD: Human 
tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res 
2008, 68:1636-1646.
35.  Yoo NJ, Kim MS, Lee SH: Absence of COSMC gene mutations in breast and 
colorectal carcinomas. Apmis 2008, 116:154-155.
36.  Piller V, Piller F, Cartron JP: Comparison of the carbohydrate-binding 
specifi  cities of seven N-acetyl-D-galactosamine-recognizing lectins. Eur J 
Biochem 1990, 191:461-466.
37. Brooks  SA:  The involvement of Helix pomatia lectin (HPA) binding 
N-acetylgalactosamine glycans in cancer progression. Histol Histopathol 
2000, 15:143-158.
38. Springer  GF:  Immunoreactive T and Tn epitopes in cancer diagnosis, 
prognosis, and immunotherapy. J Mol Med 1997, 75:594-602.
39.  Wang BL, Springer GF, Carlstedt SC: Quantitative computerized image 
analysis of Tn and T (Thomsen–Friedenreich) epitopes in prognostication 
of human breast carcinoma. J Histochem Cytochem 1997, 45:1393-1400.
40.  Korourian S, Siegel E, Kieber-Emmons T, Monzavi-Karbassi B: Expression 
analysis of carbohydrate antigens in ductal carcinoma in situ of the breast 
by lectin histochemistry. BMC Cancer 2008, 8:136.
41.  Konska G, Guerry M, Caldefi  e-Chezet F, De Latour M, Guillot J: Study of the 
expression of Tn antigen in diff  erent types of human breast cancer cells 
using VVA-B4 lectin. Oncol Rep 2006, 15:305-310.
42.  Kawaguchi T, Takazawa H, Imai S, Morimoto J, Watanabe T, Kanno M, Igarashi 
S: Expression of Vicia villosa agglutinin (VVA)-binding glycoprotein in 
primary breast cancer cells in relation to lymphatic metastasis: is atypical 
MUC1 bearing Tn antigen a receptor of VVA? Breast Cancer Res Treat 2006, 
98:31-43.
43.  Brooks SA, Leathem AJ: Prediction of lymph node involvement in breast 
cancer by detection of altered glycosylation in the primary tumour. Lancet 
1991, 338:71-74.
44.  Leathem AJ, Brooks SA: Predictive value of lectin binding on breast-cancer 
recurrence and survival. Lancet 1987, 1:1054-1056.
45.  Danussi C, Coslovi A, Campa C, Mucignat MT, Spessotto P, Uggeri F, Paoletti S, 
Colombatti A: A newly generated functional antibody identifi  es Tn antigen 
as a novel determinant in the cancer cell–lymphatic endothelium 
interaction. Glycobiology 2009, 19:1056-1067.
46.  van Vliet SJ, Saeland E, van Kooyk Y: Sweet preferences of MGL: 
carbohydrate specifi  city and function. Trends Immunol 2008, 29:83-90.
47.  Saeland E, van Vliet SJ, Backstrom M, van den Berg VC, Geijtenbeek TB, Meijer 
GA, van Kooyk Y: The C-type lectin MGL expressed by dendritic cells 
detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol 
Immunother 2007, 56:1225-1236.
48.  Napoletano C, Rughetti A, Agervig Tarp MP, Coleman J, Bennett EP, Picco G, 
Sale P, Denda-Nagai K, Irimura T, Mandel U, Clausen H, Frati L, Taylor-
Papadimitriou J, Burchell J, Nuti M: Tumor-associated Tn-MUC1 glycoform is 
internalized through the macrophage galactose-type C-type lectin and 
delivered to the HLA class I and II compartments in dendritic cells. Cancer 
Res 2007, 67:8358-8367.
49.  Julien S, Delannoy P: Sialyl-Tn antigen in cancer: from diagnosis to therapy. 
In Recent Research Developments in Cancer. Volume 5. Edited by Pandalai SG. 
Kerala: Transworld Research Network; 2003:185-199.
50.  Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, Gouyer V, Huet G, Le 
Bourhis X, Delannoy P: Expression of sialyl-Tn antigen in breast cancer cells 
transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-
sialyltransferase (ST6GalNac I) cDNA. Glycoconj J 2001, 18:883-893.
51.  Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gatgens 
J, Clausen H, Hansson GC, Burchell J, Taylor-Papadimitriou J: The ST6GalNAc-I 
sialyltransferase localizes throughout the Golgi and is responsible for the 
synthesis of the tumor-associated sialyl-Tn O-glycan in human breast 
cancer. J Biol Chem 2006, 281:3586-3594.
52.  Gold DV, Mattes MJ: Monoclonal antibody B72.3 reacts with a core region 
structure of O-linked carbohydrates. Tumour Biol 1988, 9:137-144.
53.  Reddish MA, Jackson L, Koganty RR, Qiu D, Hong W, Longenecker BM: 
Specifi  cities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated 
using novel clustered synthetic glycopeptide epitopes. Glycoconj J 1997, 
14:549-560.
54.  Ogata S, Koganty R, Reddish M, Longenecker BM, Chen A, Perez C, Itzkowitz 
SH: Diff  erent modes of sialyl-Tn expression during malignant 
transformation of human colonic mucosa. Glycoconj J 1998, 15:29-35.
55.  Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, 
Buzdar AU, Frye DK, Dhingra K: The prognostic signifi  cance of sialyl-Tn 
antigen in women treated with breast carcinoma treated with adjuvant 
chemotherapy. Cancer 1997, 80:2240-2249.
56.  Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C: STn and 
prognosis in breast cancer. Oncology 2001, 61:299-305.
57.  Clement M, Rocher J, Loirand G, Le Pendu J: Expression of sialyl-Tn epitopes 
on beta1 integrin alters epithelial cell phenotype, proliferation and 
haptotaxis. J Cell Sci 2004, 117(Pt 21):5059-5069.
58.  Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, 
Taylor-Papadimitriou J, Burchell JM: Sialyl-Tn vaccine induces antibody-
mediated tumour protection in a relevant murine model. Br J Cancer 2009, 
100:1746-1754.
59.  Ravn V, Dabelsteen E: Tissue distribution of histo-blood group antigens. 
Apmis 2000, 108:1-28.
60.  Kaneko M, Kudo T, Iwasaki H, Ikehara Y, Nishihara S, Nakagawa S, Sasaki K, 
Shiina T, Inoko H, Saitou N, Narimatsu H: Alpha1,3-fucosyltransferase IX 
(Fuc-TIX) is very highly conserved between human and mouse; molecular 
cloning, characterization and tissue distribution of human Fuc-TIX. FEBS 
Lett 1999, 452:237-242.
61.  Mollicone R, Gibaud A, Francois A, Ratcliff  e M, Oriol R: Acceptor specifi  city 
and tissue distribution of three human alpha-3-fucosyltransferases. Eur 
J Biochem 1990, 191:169-176.
62.  Natsuka S, Gersten KM, Zenita K, Kannagi R, Lowe JB: Molecular cloning of a 
cDNA encoding a novel human leukocyte alpha-1,3-fucosyltransferase 
capable of synthesizing the sialyl Lewis x determinant. J Biol Chem 1994, 
269:16789-16794.
63.  Kitagawa H, Paulson JC: Cloning and expression of human Gal beta 1,3(4)
GlcNAc alpha 2,3-sialyltransferase. Biochem Biophys Res Commun 1993, 
194:375-382.
64.  Ellies LG, Sperandio M, Underhill GH, Yousif J, Smith M, Priatel JJ, Kansas GS, 
Ley K, Marth JD: Sialyltransferase specifi  city in selectin ligand formation. 
Blood 2002, 100:3618-3625.
65.  Kukowska-Latallo JF, Larsen RD, Nair RP, Lowe JB: A cloned human cDNA 
determines expression of a mouse stage-specifi  c embryonic antigen and 
the Lewis blood group alpha(1,3/1,4)fucosyltransferase. Genes Dev 1990, 
4:1288-1303.
66.  Sasaki K, Kurata K, Kojima N, Kurosawa N, Ohta S, Hanai N, Tsuji S, Nishi T: 
Expression cloning of a GM3-specifi  c alpha-2,8-sialyltransferase 
(GD3 synthase). J Biol Chem 1994, 269:15950-15956.
67.  Maly P, Thall A, Petryniak B, Rogers CE, Smith PL, Marks RM, Kelly RJ, Gersten 
KM, Cheng G, Saunders TL, Camper SA, Camphausen RT, Sullivan FX, Isogai Y, 
Hindsgaul O, von Andrian UH, Lowe JB: The alpha(1,3)fucosyltransferase 
Fuc-TVII controls leukocyte traffi   cking through an essential role in L-, E-, 
and P-selectin ligand biosynthesis. Cell 1996, 86:643-653.
68.  Renkonen J, Paavonen T, Renkonen R: Endothelial and epithelial expression 
of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J 
Cancer 1997, 74:296-300.
69.  Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, 
Takagi H: Increased level of circulating adhesion molecules in the sera of 
breast cancer patients with distant metastases. Jpn J Clin Oncol 1997, 
27:135-139.
70.  Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese 
K: Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in 
human breast cancer: immunohistochemical analysis in mammary 
carcinoma in situ, invasive carcinomas and their lymph node metastasis. 
Anticancer Res 2005, 25:1615-1622.
71.  Nakagoe T, Fukushima K, Itoyanagi N, Ikuta Y, Oka T, Nagayasu T, Ayabe H, 
Hara S, Ishikawa H, Minami H: Expression of ABH/Lewis-related antigens as 
prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 
2002, 128:257-264.
72.  Matsuura N, Narita T, Hiraiwa N, Hiraiwa M, Murai H, Iwase T, Funahashi H, Imai 
T, Takagi H, Kannagi R: Gene expression of fucosyl- and sialyl-transferases 
which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in 
Cazet et al. Breast Cancer Research 2010, 12:204 
http://breast-cancer-research.com/content/12/3/204
Page 12 of 13human breast cancer. Int J Oncol 1998, 12:1157-1164.
73.  Hsu CC, Lin TW, Chang WW, Wu CY, Lo WH, Wang PH, Tsai YC: Soyasaponin-I-
modifi  ed invasive behavior of cancer by changing cell surface sialic acids. 
Gynecol Oncol 2005, 96:415-422.
74.  Idikio HA, Manickavel V: Lewis blood group antigens (a and b) in human 
breast tissues. Loss of Lewis-b in breast cancer cells and correlation with 
tumor grade. Cancer 1991, 68:1303-1308.
75.  Abd Hamid UM, Royle L, Saldova R, Radcliff  e CM, Harvey DJ, Storr SJ, Pardo M, 
Antrobus R, Chapman CJ, Zitzmann N, Robertson JF, Dwek RA, Rudd PM: 
A strategy to reveal potential glycan markers from serum glycoproteins 
associated with breast cancer progression. Glycobiology 2008, 
18:1105-1118.
76.  Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, 
Nakashima K, Tanaka K, Sonoo H: Combined measurement of serum sialyl 
Lewis X with serum CA15-3 in breast cancer patients. Jpn J Clin Oncol 2006, 
36:150-153.
77.  Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE: Highly tumor-reactive, 
internalizing, mouse monoclonal antibodies to Le(y)-related cell surface 
antigens. Cancer Res 1990, 50:2183-2190.
78.  Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG: High 
expression of Lewis y/b antigens is associated with decreased survival in 
lymph node negative breast carcinomas. Breast Cancer Res 2005, 
7:R780-R787.
79.  Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM: Enhanced effi   cacy of 
90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 
and paclitaxel combined-modality radioimmunotherapy in a breast 
cancer model. J Nucl Med 2006, 47:716-725.
80.  Pinho SS, Reis CA, Gartner F, Alpaugh ML: Molecular plasticity of E-cadherin 
and sialyl lewis x expression, in two comparative models of mammary 
tumorigenesis. PLoS One 2009, 4:e6636.
81. Tettamanti  G:  Ganglioside/glycosphingolipid turnover: new concepts. 
Glycoconj J 2004, 20:301-317.
82.  Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S: 
Gangliosides expressed in human breast cancer. Cancer Res 1996, 
56:5165-5171.
83.  Oliva JP, Valdes Z, Casaco A, Pimentel G, Gonzalez J, Alvarez I, Osorio M, 
Velazco M, Figueroa M, Ortiz R, Escobar X, Orozco M, Cruz J, Franco S, Díaz M, 
Roque L, Carr A, Vázquez AM, Mateos C, Rubio MC, Pérez R, Fernández LE: 
Clinical evidences of GM3 (NeuGc) ganglioside expression in human 
breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. 
Breast Cancer Res Treat 2006, 96:115-121.
84.  Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiff  mann S, 
Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M: Microarray analysis 
of altered sphingolipid metabolism reveals prognostic signifi  cance of 
sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008, 
112:41-52.
85.  Ruckhaberle E, Karn T, Rody A, Hanker L, Gatje R, Metzler D, Holtrich U, 
Kaufmann M: Gene expression of ceramide kinase, galactosyl ceramide 
synthase and ganglioside GD3 synthase is associated with prognosis in 
breast cancer. J Cancer Res Clin Oncol 2009, 135:1005-1013.
86.  Gu Y, Zhang J, Mi W, Yang J, Han F, Lu X, Yu W: Silencing of GM3 synthase 
suppresses lung metastasis of murine breast cancer cells. Breast Cancer Res 
2008, 10:R1.
87.  Goss PE, Baker MA, Carver JP, Dennis JW: Inhibitors of carbohydrate 
processing: a new class of anticancer agents. Clin Cancer Res 1995, 
1:935-944.
88.  Paszkiewicz-Gadek A, Porowska H, Lemancewicz D, Wolczynski S, Gindzienski 
A: The infl  uence of N- and O-glycosylation inhibitors on the glycosylation 
profi  le of cellular membrane proteins and adhesive properties of 
carcinoma cell lines. Int J Mol Med 2006, 17:669-674.
89.  Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, 
Ferrari M: Nanotechnology for breast cancer therapy. Biomed Microdevices 
2009, 11:49-63.
90.  Lo NW, Dennis JW, Lau JT: Overexpression of the alpha2,6-sialyltransferase, 
ST6Gal I, in a low metastatic variant of a murine lymphoblastoid cell line is 
associated with appearance of a unique ST6Gal I mRNA. Biochem Biophys 
Res Commun 1999, 264:619-621.
91. Taniguchi  A:  Promoter structure and transcriptional regulation of human 
beta-galactoside alpha2, 3-sialyltransferase genes. Curr Drug Targets 2008, 
9:310-316.
92.  Glinsky VV, Hufl  ejt ME, Glinsky GV, Deutscher SL, Quinn TP: Eff  ects of 
Thomsen–Friedenreich antigen-specifi  c peptide P-30 on beta-
galactoside-mediated homotypic aggregation and adhesion to the 
endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 
2000, 60:2584-2588.
93.  Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, 
Glinsky VV, Rittenhouse-Olson K: Inhibition of spontaneous breast cancer 
metastasis by anti-Thomsen–Friedenreich antigen monoclonal antibody 
JAA-F11. Neoplasia 2006, 8:939-948.
94.  Fernandez LE, Alonso DF, Gomez DE, Vazquez AM: Ganglioside-based 
vaccines and anti-idiotype antibodies for active immunotherapy against 
cancer. Expert Rev Vaccines 2003, 2:817-823.
95.  Vazquez AM, Gabri MR, Hernandez AM, Alonso DF, Beausoleil I, Gomez DE, 
Perez R: Antitumor properties of an anti-idiotypic monoclonal antibody in 
relation to N-glycolyl-containing gangliosides. Oncol Rep 2000, 7:751-756.
96.  Fuentes D, Avellanet J, Garcia A, Iglesias N, Gabri MR, Alonso DF, Vazquez AM, 
Perez R, Montero E: Combined therapeutic eff  ect of a monoclonal anti-
idiotype tumor vaccine against NeuGc-containing gangliosides with 
chemotherapy in a breast carcinoma model. Breast Cancer Res Treat 2010, 
120:379-389.
97.  Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, Diaz RM, Perez R, 
Vazquez AM: Immune responses in breast cancer patients immunized with 
an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin 
Immunol 2003, 107:80-89.
98.  Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vazquez AM, 
Fainboim L: Cellular and humoral immune response to N-Glycolyl-GM3 
elicited by prolonged immunotherapy with an anti-idiotypic vaccine in 
high-risk and metastatic breast cancer patients. J Immunother 2006, 
29:215-223.
99.  Miles D, Papazisis K: Rationale for the clinical development of STn-KLH 
(Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer 
2003, 3(Suppl 4):S134-S138.
100.  Slovin SF, Ragupathi G, Fernandez C, Diani M, Jeff  erson MP, Wilton A, Kelly WK, 
Morris M, Solit D, Clausen H, Livingston P, Scher HI: A polyvalent vaccine for 
high-risk prostate patients: ‘are more antigens better?’ Cancer Immunol 
Immunother 2007, 56:1921-1930.
doi:10.1186/bcr2577
Cite this article as: Cazet A, et al.: Tumour-associated carbohydrate antigens 
in breast cancer. Breast Cancer Research 2010, 12:204.
Cazet et al. Breast Cancer Research 2010, 12:204 
http://breast-cancer-research.com/content/12/3/204
Page 13 of 13